The American Journal of Managed Care

FDA Approves Talazoparib Plus Enzalutamide for mCRPC With HRR Gene Mutations

Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with ...
The American Journal of Managed Care

FDA Approves Olaparib for HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer

The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior ...
ascopubs.org

Exploratory analyses of homologous recombination repair (HRR) gene subgroups and potential associations with secondary efficacy endpoints in the HRR-deficient population from ...

Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model. The ...
ascopubs.org

Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant ...

Management disparities in metastatic castrate-sensitive prostate cancer (mCSPC). This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers Symposium. This abstract does not include a ...
Cure Today

FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer

The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...